Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Investment Conference. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat on September 9, 2025, at 2:30 p.m. ET, moderated by Biotech Equity Research Analyst Emily Bodnar.
The company will also conduct one-on-one meetings with institutional investors during the conference. A replay of the session will be available for approximately 90 days on Genelux's IR page.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GNLX declined 1.78%, reflecting a mild negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $134M at that time.
Data tracked by StockTitan Argus on the day of publication.
WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at H.C. Wainwright & Co’s Annual Global Investment Conference on Tuesday, September 9, 2025.
Biotech Equity Research Analyst, Emily Bodnar, will moderate the session which is scheduled to begin at 2:30 p.m. ET. To register for and view the session, please use the link https://journey.ct.events/view/6248b37e-6c86-47e2-8bd2-0e03637b46e4. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact genelux@allelecomms.com
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (NASDAQ: GNLX) presenting at the H.C. Wainwright Conference?
Who will represent Genelux at the H.C. Wainwright Conference?
How can investors access Genelux's H.C. Wainwright Conference presentation?
How can institutional investors arrange meetings with Genelux management?
